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algorithms were used for the dose calculation of the TPS. Moreover, 
the pencil beam algorithm was used for the dose calculation in the MU 
calculation software. The prescribed dose was 200 MU for 6/10 MV 
photon beams (Trilogy, Varian Medical Systems). Dose measurements 
were performed using an ion chamber and a water phantom. 
Results: Figure 1 shows that the dose difference between the dose 
calculated by the MU calculation software and the measured dose for 
6/10 MV photon beams was -0.5 ± 0.5% and -0.6 ± 0.6%, with the 
largest dose difference being -1.8% and -1.9%, respectively.  
Table 1 shows that the dose differences between the doses calculated 
by the MU calculation software and the TPS were 0.3 ± 0.7% (SP), -0.1 
± 0.7% (CO), -0.1 ± 1.0% (CL), 0.3 ± 0.6% (AAA), and 0.4 ± 0.7% (PBC), 
with the largest dose difference being 2.4%, -3.0%, -4.3%, 1.9%, and 
2.5%, respectively. All dose differences exceeding ±3% were caused by 
the physical wedge.  
 Figure 1. Dose difference between measured doses and doses 
calculated by the MU calculation software. 
 
Table 1. Dose difference between the doses calculated by the MU 
calculation software and the TPS for homogeneous conditions. 
 
 
Conclusions: The dose calculated by the MU calculation software was 
in agreement with the measured dose within ±2%. Moreover, the doses 
calculated by the MU calculation software and TPS were in agreement 
within ±3%, except for the Clarkson algorithm. Although the dose 
difference exceeded ±3% in verification plans of a physical wedge, in 
all verification plans, the result of dose calculation by the MU 
calculation software was less than the action levels of TG-114. Use of 
the MU calculation software offered sufficient accuracy in dose 
calculation for verifying the MU calculation, and it is an effective 
method for clinical use.  
   
EP-1197   
Modelling electron beams of elekta linacs with a Monte Carlo dose 
algorithm in pinnacle 
I. Rüssel1, W. Schillemans2, A. Petoukhova1, H. Huizenga3, A. Holt4, E. 
Damen4, E. Korevaar5, M. Bal6, J. Van Santvoort1 
1Haaglanden Medical Centre, Radiotherapy Centre West, The Hague, 
The Netherlands  
2Erasmus Medical Centre, Radiotherapy, Rotterdam, The Netherlands  
3Radboud Medical Centre, Radiotherapy, Nijmegen, The Netherlands  
4Netherlands Cancer Institute, Radiotherapy, Amsterdam, The 
Netherlands  
5University Medical Centre, Radiotherapy, Groningen, The 
Netherlands  
6Philips, Radiation Oncology Systems, Best, The Netherlands  
  
Purpose/Objective: To model the electron beams of Elekta SLi 
accelerators with the Monte Carlo algorithm of the research version of 
the Pinnacle treatment planning system (Pinnacle version 9.100, 
Philips Healthcare). The other goals of this work are to determine the 
effort needed to adapt models to a specific machine and to determine 
the accuracy of the electron beam model in the research version of 
Pinnacle. 
Materials and Methods: Anextensive set of measured electron beam 
data of two Elekta SLi accelerators (PDD, profiles on various depths, 
and output factors, multiple energies and applicator sizes) was 
available from Institution 3, and beam models based on limited data 
were available from Institution 4 and 5. The Monte Carlo algorithm 
uses a forward modelling from the source to the fluence plane 
approach. First, a single new model was built from the data measured 
by Institution 3 and the existing models. Afterwards, output factors 
were calculated and the machine was commissioned. Then, the 
accuracy of the single model was evaluated. Secondly, by comparing 
the model with measurement data from Institution 1, it was tested 
which parameters of the model needed adaptation to adequately 
describe the beam data of institution 1. 
Results: Modeling took 3 days (due to calculation time) per energy 
with five applicator sizes. Calculation of output factors took about 
7days per energy at a machine with two AMD Opteron 254 processors 
and with 16 GB RAM. The measured data of institution 3 could be 
modeled with a single forward model for 9 and 12 MeV, resulting in a 
maximum of 3% deviation in PDD and profiles (according to Fig 1) for 
all applicator sizes (see Fig. 1A for 12 MeV, 10x10cm2 frame). For 6, 
15, 18 MeV a second model was required to reach this result. The 
comparison of the model with measured data from Institution 1 
resulted in small differences in PDD and profiles. Beam energy was 
somewhat higher in the model, and profiles were narrower (Fig 1B). 
Therefore,only small obvious changes were required to model the 
data of Institution 1 accurately (e.g. to account for a different field 
size definition (at 95 cm instead of 100 cm) and reference depth). 
Performing these changes of model took only 2 hours per energy. Fig. 
1C shows the model for Institution 1. 
 
Figure 1. PDD and X profiles at the depth of 1.9cm for 12MeV and 
10x10cm2 applicator. A: Data from Institution 3 (solid line) and 
corresponding model (dashed line). B: Institution 3 data (solid line) 
and adapted model for Institution 1 data (dashed line). C: Data from 
Institution1 (solid line) and corresponding model (dashed line). 
  
Conclusions: Starting from a set of electron beam models of similar 
machines, commissioning of Elekta SLi linacs in the Pinnacle 
treatment planning system is achievable in a limited amount of time 
by fitting specific calibration settings only. 
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Purpose/Objective: In the Philips Pinnacle treatment planning system 
v9.2 it is possible to interpolate the control points of a VMAT plan 
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from a 4 degree spacing to a 2 degree spacing. In this study we 
evaluated the effect of control point interpolation on the dose 
distribution in the patient and on plan delivery at the linac.  
Materials and Methods: VMAT plans to treat stage III lung tumours 
were created for 8 patients. All plans were optimized with a 4 degree 
control point spacing. When the plan was clinically acceptable the 
control point spacing was interpolated to 2 degrees. For both plans we 
compared the coverage of the 95% isodose of the PTV minus lung 
tissue,the PTV max dose, the mean lung dose, the lung V20 and the 
maximum dose in the myelum.  
Both plans (interpolated and original) were send to the record and 
verify system (MosaiQ) and irradiated on a cubic solid water phantom 
(30x30x20 cm) using an Elekta Synergy linac. The dose in the isocenter 
was verified using a pinpoint ionisation chamber. In a consecutive 
session, the dose in the coronal isocentric plane was measured using 
the Octavius detector 729. Monitor units per control point were scaled 
in Pinnacle using a script to compensate for the angular dependence 
of the sensitivity of the detector. For both types of plans we 
compared the results of the measurements and the duration of the 
treatment. To compare array measurements and planned dose we 
used a gamma criterion of 2mm/2%. The dosecriterion was taken 
relative to the isocentric dose in the phantom. Doses below 30% of the 
maximum measured dose were excluded from the gamma calculation. 
Results: Effects of control point interpolation on the PTV-lung 
coverage, mean lung dose and lung V20 were negligible. PTV max dose 
was on average 0,8% higher in the interpolated plans, with a maximum 
of 2,2%. The mean increase in the maximum dose in the myelum was 
0,1 Gy with a maximum of 0,4 Gy. 
The accuracy of the pinpoint measurements for the original and 
interpolated plans were not statistically significant: average 
difference between planned isocentric dose and measured dose was -
0,3% (SD 1,6%) for 4 degree control point spacing and -1,3% (SD 1,1%) 
for 2 degree control point spacing. 
For the 4 degrees per control point plans we measured an average 
gamma pass rate of 82,4% with the best plan having a pass rate of 
90,0% and the worst plan a 73,6% pass rate. For the interpolated plans 
the average pass rate was 82,2% while the best and worst plan had a 
pass rate of 89,0% and 70,8% respectively. 
Finally we also measured the delivery time of the original and 
interpolated plans and observed that interpolated plans always took 
longer to deliver with a mean delivery time of 103,5 seconds 
compared to 94,5 seconds for a 4 degree spacing plan. 
Conclusions: We observed that interpolation of control point spacing 
from 4 to 2 degrees does not increase the agreement of measurement 
and dose calculation. In addition, the effect on the DVH parameters is 
negligible while both the time needed for planning and delivery 
increases. We therefore refrain from using control point interpolation 
in our clinic. 
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Purpose/Objective: To retrospectively evaluate the influence of 
intravenous contrast agent on dose calculation in CT-based three-
Dimensional-Conformal-Radiation-Therapy (3D-CRT) for pelvis and 
head-and-neck cancer patients, using two different dose calculation 
algorithms, Dose-Volume Histograms (DVHs) and 3D gamma index 
analysis. 
Materials and Methods: We randomly selected 10 pelvis and 10 head-
and-neck patients, for which two sets of CT images were acquired in 
the same position, before and after intravenous contrast agent 
injection. CT-based planning was performed in Eclipse treatment 
planning system, version 10, using Analytical Anisotropic Algorithm 
(AAA), with a calculation grid of 2.5 mm, and applying heterogeneity 
correction. A radiation oncologist contoured the target volumes and 
organs at risk (OARs) on the CT images without contrast, after 
registering them with CT images with contrast. A treatment plan was 
performed on the CT scan without contrast, and then copied to the CT 
scan with contrast using the same planning data when recalculating 
the dose. Re-plans were similarly performed on Monaco treatment 
planning system, version 3.0, using a Monte Carlo (MC) dose 
calculation algorithm, with a calculation grid of 2.5 mm and 1% 
variance. DVHs from these plans were analyzed. 
The statistical data analysis was performed using the Wilcoxon 
matched pairs test; a p-value of < 0.05 was considered significant. A 
3D gamma index analysis was performed, and the differences in dose 
distribution between two plans evaluated, for various combinations of 
distance-to-agreement (DTA) of 1 mm, 2 mm, and 3 mm and dose 
difference criteria of 2%, 3%, 4%, and 5%. 
Results: DVH analysis showed no significant difference between with 
and without contrast CT treatment plans. 
 
Table 1. The mean and maximum percentage dose difference 
between CT images with and without contrast for pelvis and head-
and-neck patients  
 
 Percentage dose
difference 
(%) 
AAA 
algorithm 
(mean ± SD) 
p-
value 
MC 
algorithm 
(mean ± 
SD) 
p-value 
Pelvis cases (n = 10) 
PTV Mean  0.1 ± 0.4 > 0.2 0.2 ± 0.7 > 0.2 
Maximum 0.3 ± 0.9 > 0.2 0.4 ± 0.8 0.1 < p < 
0.2 
Rectum Mean  0.1 ± 0.4 > 0.2 0.1 ± 0.6 > 0.2 
Maximum 0.1 ± 0.4 > 0.2 0.4 ± 0.7 0.1 < p < 
0.2 
Bladder Mean  0.1 ± 0.4 > 0.2 0.1 ± 1 > 0.2 
Maximum 0.2 ± 0.6 > 0.2 0.2 ± 0.7 > 0.2 
Head-and-neck cases (n = 10) 
PTV 60 Mean  0.1 ± 0.4 > 0.2 0.3 ± 0.9 > 0.2 
Maximum 0.4 ± 0.7 > 0.2 0.4 ± 0.8 0.02 < p 
< 0.05 
PTV 54 Mean  0.1 ± 0.6 > 0.2 0.2 ± 0.4 > 0.2 
Maximum 0.1 ± 1.7 > 0.2 0.3 ± 0.8 0.05 < p 
< 0.1 
Spinal 
cord 
Mean  0.1 ± 0.4 > 0.2 0.1 ± 1.7 > 0.2 
Maximum 0.4 ± 1 > 0.2 0.4 ± 1.5 > 0.2 
Brain 
stem 
Mean  0.2 ± 0.6 > 0.2 0.2 ± 2.5 > 0.2 
Maximum 0.1 ± 0.5 > 0.2 1.1 ± 2.1 0.05 < p 
< 0.1 
Left 
parotid 
Mean  0.3 ± 0.9 > 0.2 1 ± 2.2 > 0.2 
Maximum 0.4 ± 0.7 > 0.2 0.6 ± 1.6 0.1 < p < 
0.2 
Right 
parotid 
Mean  0.3 ± 0.9 > 0.2 1.3 ± 1.7 > 0.2 
Maximum 0.4 ± 0.8 > 0.2 0.5 ± 1.6 0.02 < p 
< 0.05 
 
Figure 1. 3D Gamma analysis window showing the gamma distribution 
for MC dose calculation algorithm and representative pelvis (a) and 
head-and-neck (b) patients, as coronal view. The red areas represent 
the points failing gamma criteria for 2 mm DTA and 2% dose 
difference. 
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